 reuters    three members of the u s  senate judiciary committee  ahead of a planned hearing late this month  said mylan nv appears to have greatly overcharged the military for its lifesaving allergy treatment epipen and asked the pharmaceutical company when it plans to reimburse the department of defense  the reimbursement demand came in a letter on monday to mylan chief executive heather bresch  from senate judiciary chairman charles grassley  an iowa republican  and committee members richard blumenthal of connecticut and amy klobuchar of minnesota  both democrats   we are alarmed that mylan may have overcharged our military for this life saving drug   the senators wrote  they said mylan for years may have knowingly misclassified epipen as a generic product in order to avoid higher rebates the company would have had to pay state and federal medicaid programs had it been classified as a branded product  the medicaid rebate for a generic is  percent compared with a minimum of   percent for a branded medicine  mylan spokeswoman nina devlin declined to comment on the letter  or its demands  the drug company has come under fire from consumers and politicians in recent months for raising the u s  list price on a pack of two epipen injectors nearly six fold to   since   lawmakers  including grassley  have called for investigations into mylan s pricing  helping put the product in the spotlight amid a larger debate over big drug price increases in the united states   pentagon spending on epipen jumped to   million over the past year from   million in   an increase driven by volume and by hefty price hikes that had a bigger bite on prescriptions filled at retail pharmacies  reuters reported on oct    citing previously unreported data    the pentagon gets a government discount on epipens dispensed at military treatment facilities and by mail order  but nearly half of its spending was at retail pharmacies where it most recently paid an average of   for epipen and   for epipen jr two packs   three times higher than its discounted rate  according to the data  the senate judiciary committee is slated to hold a hearing  nov   on epipen pricing and related matters     